Key Insights

Highlights

Success Rate

84% trial completion

Published Results

24 trials with published results (42%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

10.5%

6 terminated out of 57 trials

Success Rate

84.2%

-2.3% vs benchmark

Late-Stage Pipeline

12%

7 trials in Phase 3/4

Results Transparency

75%

24 of 32 completed with results

Key Signals

24 with results84% success

Data Visualizations

Phase Distribution

51Total
Not Applicable (6)
P 1 (15)
P 2 (23)
P 3 (7)

Trial Status

Completed32
Active Not Recruiting7
Terminated6
Recruiting5
Unknown3
Not Yet Recruiting3

Trial Success Rate

84.2%

Benchmark: 86.5%

Based on 32 completed trials

Clinical Trials (57)

Showing 20 of 20 trials
NCT02834013Phase 2Active Not Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT07454642Phase 1Recruiting

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

NCT02257528Phase 2Active Not RecruitingPrimary

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

NCT02466971Phase 3Active Not Recruiting

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

NCT07020117Phase 1Recruiting

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

NCT07276360Phase 2Recruiting

Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda

NCT07398313Not ApplicableCompletedPrimary

Effect of Prehabilitation on Recovery Outcomes in Post-Surgical Cervical Cancer Women

NCT04622670Not ApplicableActive Not RecruitingPrimary

Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer

NCT06654011Phase 2RecruitingPrimary

IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

NCT01048853Not ApplicableTerminatedPrimary

Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer

NCT03738228Phase 1CompletedPrimary

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

NCT07153952Phase 1Active Not RecruitingPrimary

RT for Adenocarcinoma/Adenosquamous Carcinoma

NCT07141186Phase 2Not Yet Recruiting

QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

NCT06543576Phase 1RecruitingPrimary

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

NCT02140021Not ApplicableTerminatedPrimary

Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

NCT01101451Phase 3CompletedPrimary

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

NCT06805864Phase 2Not Yet RecruitingPrimary

Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma

NCT06783153Phase 1Not Yet Recruiting

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

NCT02020707Phase 1CompletedPrimary

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02164461Phase 1Completed

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

Scroll to load more

Research Network

Activity Timeline